Dishman Carbogen Amcis Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/d29h5grejszkh1ydjkuwtcc5.pdf

Key Takeaways


Carbogen Amcis Switzerland: The Quarter’s Engine

Pascal Villemagne: "We are extremely depending from the success of the clinical trials, from our customer. And yes, from time-to-time, we face some issues, because we have to find a new project to replace the one we just lost. This is a reason why I'm consistent with the sales teams to border the customer portfolio. And the more customer, the more projects we have, the relationship would be to one off a project loss."

Bavla Site: Regulatory Clearance as the Revenue Catalyst

Harshil Dalal: "Absolutely. And it should be even higher than that. With the kind of orders that we are expecting from our existing customers, plus, it opens up the door to get more orders from the new customers as well. So, we do expect a significant ramp up in the revenues after the EDQM clearance, in the financial year after EDQM clearance."

French Facility: Investment Phase Nearing Its End

Pascal Villemagne: "We are finalizing all the qualifications and we run our first what we so called technical batch, and we should start the operational work by the end of this month. And then starting the first development work with our customers over September, so which is a good news."

India Business: Back-Ended but Promising


Phase 3 Pipeline: Commercialisation Is a FY25 Story


Costs, Debt and the Path to Deleveraging

Pascal Villemagne: "Obviously, we are still struggling with a number of external factors depending on the country's especially in Europe, cost of energy and raw materials are still affecting our performance."

Guidance & Commitments

CommitmentSpecificsTimeline
Full-year revenueINR 2,700–2,750 croresFY24
India API revenueIn excess of INR 300 croresFY24
French facility operational startDevelopment work with customers beginsSeptember 2023
French facility commercial revenueFirst contributionQ3 FY24
EDQM audit at BavlaInspection to take placeSecond half of September 2023
Revenue growthAt least 12–15% per yearNext 3–5 years
EBITDA growthAbout 15–20% YoYOngoing
Net debt reductionReduce from current levels using free cash flowWithin 3 years
Run-rate CapExCHF 2.5–3 crore per yearNext 3 years
ADC linker commercialisationNew applications marketedBy 2025

Key Metrics

MetricQ1 FY24
Revenue₹723 cr, +34% YoY from ₹540 cr
Full-year revenue guidance₹2,700 cr to ₹2,750 cr
COGS~22% of revenue, vs ~20% annual estimate
EBITDA~₹127 cr, after excluding SaaS IT cost
EBITDA margin17.5%, up from 16.5% in Q1 FY23
Finance cost₹28 cr, up from ₹19 cr in Q1 FY23 due to higher LIBOR/SOFR rates
Profit before tax~₹29.5 cr, vs negative ₹3 cr in Q1 FY23
Profit after tax₹17 cr, vs ₹4 cr in Q1 FY23
CRAMS segment revenue₹561 cr, +54% YoY from ₹363 cr
CRAMS segment EBITDA margin21.7%, up from 19.4% in Q1 FY23
Cholesterol and Vitamin D analogues revenue₹93 cr, +46.7% YoY from ₹63 cr
Cholesterol and Vitamin D analogues EBITDA margin18.4%, down from 19.3% in Q1 FY23
India quats and generics revenue~₹30 cr, lower on run-rate basis; pickup expected in remaining nine months
India API full-year revenue targetIn excess of ₹300 cr
Carbogen Amcis Switzerland commercial revenue$30.5 mn, up from $11.5 mn in Q1 FY23
Development pipeline valueCHF 12.6 cr, up 10% QoQ
French facility P&L cost debited€0.27 cr in Q1 FY24
French facility purchase orders received~$6 mn before commercial start
French facility peak revenue target$30 mn to $40 mn
Consolidated FY24 CapEx guidance$25 mn to $30 mn
Run-rate annual CapEx (next 3 years)CHF 2.5 cr to CHF 3 cr, including maintenance
Net debtCHF 16 cr as of 30 June 2023
Gross debtCHF 21 cr as of 30 June 2023
Revenue growth guidance (3–5 years)At least 12% to 15% annually
EBITDA growth guidance15% to 20% YoY